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Background: Pulmonary hypertension (PH) is a disease associated with a high morbidity and
mortality. There is paucity of data regarding PH from the developing countries including
India.
Idiopathic pulmonary arterial hypertension is the most important etiological factor in the
western world, but PH secondary to rheumatic heart disease, chronic obstructive pulmonary
disease and untreated congenital heart disease could well be the predominant causes in
developing countries like India.
The main objective of the PROKERALA study – Pulmonary hypertension Registry Of Kerala
is to collect data regarding the etiology, practice patterns and one-year outcomes of patients
diagnosed to have PH.
Methods: The study is a hospital-based registry in the state of Kerala supported and funded
by the Cardiological Society of India, Kerala Chapter. A total of 77 hospitals have agreed to
participate in the registry. PH was deﬁned as systolic pulmonary artery pressure derived by
echocardiography of more than 50 mmHg (by tricuspid regurgitation jet) or mean PA
pressure more than 25 mmHg obtained at cardiac catheterization.
A detailed questionnaire is administered which includes the demographic character-
istics, risk factors, family history, ECG data, 6 minute walk test distance, chest X ray ﬁndings
and echocardiographic data. Details of PH speciﬁc therapy and one-year follow-up data are
collected.
From a preliminary survey in the region, we estimated that we will be able to collect 2000
cases over a period of one year.
# 2015 Cardiological Society of India. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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i n d i a n h e a r t j o u r n a l 6 8 ( 2 0 1 6 ) 7 0 9 – 7 1 5710Pulmonary hypertension (PH) is characterized by increased
pulmonary artery pressure and is associated with signiﬁcant
morbidity and mortality.1 PH is deﬁned by a mean pulmonary
artery pressure of ≥25 mmHg at rest.2
1. Background
Epidemiological data regarding PH is not available from most
of the developing world including India.3 India is likely to have
a huge burden of PH given the background of high prevalence
of rheumatic heart disease, chronic obstructive pulmonary
disease (COPD), and untreated congenital heart diseases
(CHD). The burden of PH is likely to be different in the Indian
context compared to the West, where idiopathic pulmonary
arterial hypertension and PH related to left heart diseases
predominate. In the developing world, it is postulated that PH
secondary to rheumatic heart disease, COPD, and untreated
CHD may predominate over primary PAH and PH related to left
heart diseases.
The prevalence of the various ailments which can predis-
pose to the development of PH, obtained from various
community level studies in the ﬁrst decade of the 21st century
in India include: 1.5–2 per 1000 for rheumatic heart disease (all
age groups),4 4.2/1000 for CHD (pediatric age group),5 4.5–10.5%
for ischemic heart disease.6 With this huge population having
diseases which can predispose to PH, the burden of PH is likely
to be very high in India.
Registries and surveys collect data rapidly and efﬁciently,
allowing an analysis of a disease condition over a particular
chronological interval. Registry data with its own limitations
will provide a perspective of the problem in the community,
for example – what are the etiologies leading to PH in the
population.7 Registry and survey data allow clinicians to
compare their own practice with that of larger national or
international reference populations. This provides an
important stimulation for improvements in quality and
consistency of practice. This will also help to form a
database, which can help in studying the natural history
of the disease.
There is renewed interest in PH due to the wide availability
of pulmonary vasodilator drugs like Sildenaﬁl, Tadalaﬁl,
Bosentan, and Ambrisentan which have all been found to be
effective both in primary and in some cases of secondary PH.
Over time, the cost of these drugs has also fallen making it
more affordable to the majority of Indians who spend out of
pocket. Registries also gather information regarding manage-
ment patterns and outcomes of patients that can help guide
the future strategies, which our physician community should
follow.
Echocardiography-based registries in the developing world
were found to be useful as in the case of the PAPUCO registry in
Sub-Saharan Africa. The Pan African Pulmonary Hypertension
Cohort study (PAPUCO) is an ongoing, prospective echocardi-
ography-based observational cohort study; the objective is to
describe the epidemiology and characteristics of PH in Sub-
Saharan Africa.8
In this background, we have initiated a multi-center
registry that allows organization of data regarding PH from
different hospitals in Kerala.2. Aim of the study
To initiate a registry of patients with PH from hospitals all over
Kerala for one year from January 2015 to December 2015.
3. Primary objectives
 To know the pattern of clinical presentation of PH in Kerala.
 To assess the different etiologies.
 To understand the practice pattern regarding management
of this condition among physicians in Kerala.
 To estimate the 6-month and one-year follow-up data.
4. Deﬁnitions
Patients with diagnosis of PH – deﬁned as systolic pulmonary
artery pressure (SPAP) derived by echocardiography more than
50 mmHg (by tricuspid regurgitation jet velocity method9 –
4V2 + estimated right atrial pressure, where V is the TR jet
velocity) in the absence of right ventricular outﬂow tract
obstruction2 or mean PA pressure more than 25 mmHg during
cardiac catheterization – are being enrolled into the registry.10
It was decided to capture data of all etiologies of PH
including PH associated with left heart diseases (Group 2 of the
Revised WHO classiﬁcation) for the registry. Given the chances
of heterogeneity in the diagnostic methods in participating
centers (most centers rely on echocardiography for diagnosis
with only some centers likely to undertake diagnostic invasive
cardiac catheterization based on the underlying etiology of
PH), it was decided to include echocardiographic criteria with
the SPAP of ≥50 mmHg (by estimation of the tricuspid
regurgitation jet velocity) in the absence of right ventricular
outﬂow obstruction. A higher diagnostic threshold was used
to minimize false positives. Mukerjee et al. have shown that
97% of patients with an echocardiographically determined
tricuspid gradient of >45 mmHg were found to have PH at
catheterization, and they have suggested using a higher
threshold to improve the diagnostic accuracy.11
We are using the WHO Classiﬁcation (Danapoint 2008) to
collect the information on the etiology of PH (Table 1).
5. Participating centers
Hospitals in Kerala with cardiologists, chest physicians, and
general physicians treating patients with PH were contacted
and requested to participate in the registry. A total of 65
hospitals across the state of Kerala have agreed to participate
in the registry. The list of the hospitals and the principal
investigators (PI) in those hospitals who are participating in
the registry is attached in the Appendix I.
6. Administration and functioning
The physician enrolls the patient into the registry if the
inclusion and exclusion criteria are satisﬁed and the patient is
Table 1 – WHO – Dana point classification of Pulmonary Hypertension (Table published with permission from Elsevier:
Gérald Simonneau et al. JACC 2009;54:S43–S54).12
Group 1 Pulmonary artery hypertension 1.1 Idiopathic
1.2 Hereditary 1.2.1 BMPR2
1.2.2 ALK-1, ENG, SMAD9, KCNK3.1
1.2.3 Unknown
1.3 Drug and toxin induced
1.4 Associated with 1.4.1 Connective tissue disease
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart disease
1.4.5 Schistosomiasis
1.4.6 Chronic hemolytic anemia
1.5 Persistent pulmonary hypertension of the newborn
10 Pulmonary veno-occlusive disease and/or Pulmonary capillary
hemangiomatosis
Group 2 Pulmonary hypertension owing
to left heart disease
2.1 Systolic dysfunction
2.2 Diastolic dysfunction
2.3 Valvular disease
Group 3 Pulmonary hypertension owing
to lung diseases and/or hypoxia
3.1 Chronic obstructive pulmonary disease
3.2 Interstitial lung disease
3.3 Others with mixed restrictive obstructive patterns
3.4 sleep disordered breathing
3.5 Alveolar hypoventilation disorders
3.6 Chronic exposure to high altitude
3.7 Developmental abnormalities
Group 4 CTEPH Chronic Thromboembolic
pulmonary hypertension (CTEPH)
Group 5 Unclear, multifactorial 5.1 Hematological disorders – myeloproliferative disorders,
splenectomy
5.2 Systemic disorders: sarcoidosis, pulmonary Langerhans cell
histiocytosis: lymphangioleiomyomatosis, neuroﬁbromatosis, vasculitis
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease,
thyroid disorders
5.4 Others: tumoral obstruction, ﬁbrosing mediastinitis, chronic renal
failure on dialysis
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and the information sheet is attached – Appendix II). A simple
questionnaire (study proforma) is being used to collect the
data (see Appendix III). Characteristics collected include
demographics, clinical characteristics such as mode of
presentation, duration of symptoms, and echocardiographic
data. The one-year follow-up data are also planned to be
collected.
There will be two research coordinators stationed in the
coordinating center – SCTIMST. They have been given training
in data collection by the PI of the study. These research
coordinators along with the local PI in each hospital imparted
training to the echocardiography lab nurses and technicians in
each participating center who collect the data. We had brought
out a four-page instruction booklet describing how to ﬁll the
questionnaire (Appendix IV).
The data coordinator is visiting the sites periodically
(monthly in the initial three months) and is collecting
the ﬁlled questionnaire. Onsite checks for accuracy of the
data and completeness of data are being done and the
missing data are collected there itself. The deﬁciencies
in data collection are pointed out and re-training is given
if needed. This method was found successful in the case ofKerala ACS registry13 and also the Trivandrum Heart
Failure Registry,14 which was conducted by the same team
of investigators.
7. Investigators
The six PI are from three zones (two each from Central, South,
and North regions) of Kerala. Each zonal coordinator is
overseeing the data collection from hospitals in the region.
The three co-coordinating centers are teaching hospitals,
which are also referral hospitals, which is of advantage, since
the physicians in a particular region may have a rapport with
the coordinators.
8. Funding
Funding was obtained from the Kerala Chapter of the
Cardiological Society of India (CSI-K). CSI-K has funded the
Kerala ACS registry, the largest ACS registry in the country and
also the CSI-KERALA CRP (CSIK – Cardiac Risk factor Proﬁle
study). The Kerala ACS registry was published in European
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published in Indian Heart Journal.15
9. Ethical clearance
The study was cleared by the respective Institutional Ethics
Committees of each of the participating centers. For those
hospitals which do not have their own IEC, the study proposals
were cleared by the Independent IEC of the cardiological
Society of India, Kerala Chapter.
10. Timelines
The study was initiated in January 2015. Some of the centers
had delay in getting clearance from the respective Institu-
tional Ethics committees, but the data collection in those
centers will extend from a period of one year from the date of
initiation. The follow-up also will extend accordingly in those
centers. If we could collect accurate data, we are planning to
convert this group of patients to a cohort and are also
planning to follow them up for a longer period of time – 5 years
or more.
11. Data management and analysis
Data analyses will be started after checking the data set for
quality issues and missing variables. We will generate periodic
listing of data queries for the sites to resolve data-related
issues. A database lock will be employed to ﬁnalize the data set
for statistical analyses. No statistical analyses will be
conducted before the database lock and no modiﬁcation of
data will be allowed after the database lock. In order to present
baseline characteristics, categorical variables will be presented
as proportions with their 95% conﬁdence interval. Distribution
of continuous variables will be checked and normal distribu-
tion will be ensured before applying any parametric hypothe-
sis testing. Continuous variables will be presented as means
with standard deviation. If the continuous variables are not
normally distributed, they will be presented as median with
interquartile range. Both in-hospital and one-year mortality
rate will be reported as a proportion (number of deaths/total
registered patients) and per 1000 person-days of follow-up.
Survival analyses will be employed to identify factors
associated with mortality outcomes. Univariate survival
models will be performed initially using Kaplan–Meier survival
plots and groups will be compared using log rank tests. Any
deviation from the proportional hazards assumption will be
tested using log-minus-log plots. Later, if they satisfy the
proportional hazard assumption, Cox proportional hazards
models (Cox-PH) will be employed to evaluate potentialmultivariate adjusted risks of all-cause mortality. The multi-
variate model will include all relevant covariates/confounders
based on existing literature and with a univariate p < 0.20. All
analyses will be carried out using Stata 12 (StataCorp, College
Station, TX, USA).
12. What this study is going to add to the
literature
There are no data from the developing world including India
on PH, even though 97% of the disease burden is from the
developing world. This study will seek to bridge the gap of
knowledge and will enable the physician and the research
community to take a stock of the situation and streamline
preventive and disease management strategies.
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Appendix A. Guidance to echocardiographic
measurements.
A.1. Right ventricular dimensions
See Fig. 1
A.2. Right ventricular systolic pressure
See Fig. 2
A.3. Pulmonary artery pressure – mean and diastolic
See Fig. 3
A.4. TAPSE
TAPSE or tricuspid annular plane systolic excursion is a
measure right ventricular function – the longitudinal function
of the right ventricle. TAPSE is the distance of systolic
excursion of the RV annulus along the longitudinal plane. It
is obtained from a standard apical 4-chamber window by
placing an M-mode cursor at the lateral tricuspid annulus and
measuring the amount of longitudinal motion of the annulus
at peak systole. The lower reference value for impaired RV
systolic function of 16 mm (Fig. 4).
Fig. 2 – Doppler echocardiographic determination of systolic pulmonary artery pressure (SPAP). Spectral continuous-wave
Doppler signal of tricuspid regurgitation (TR) jet is used to derive the SPAP. The TR jet velocity indicates the right ventricular
(RV) – right atrial (RA) pressure gradient. The SPAP is derived as the sum of the estimated RA pressure (RAP) and the peak
pressure gradient between the peak right ventricle and the right atrium, as estimated by application of the modified
Bernoulli equation (4 V2 where V is the velocity of the TR jet) to peak velocity represented by the tricuspid regurgitation
Doppler signal.9 The RAP was estimated from the inferior vena cava diameter. If the IVC was ≤21 mm and the deep
inspiratory collapse (‘‘sniff test’’) was >50%, RAP was estimated to be 3 mmHg; if the diameter was >21 mm and the collapse
<50%, RAP was estimated as 15 mmHg; in intermediate cases, a value of 8 mmHg was assigned.9 In this example, SPAP is
estimated at 92 + central venous pressure, or 100 mmHg, if RAP is assumed to be 8 mmHg.
Fig. 1 – Measured in the apical 4-chamber view at end-diastole. The maximum diameter of the RV should be obtained without
fore-shortening. RV diameter >42 mms at base (RVD1) or >35 mms at mid-RV (RVD2) and longitudinal RV dimension >86 mm
(RVD3) indicates RV dilatation.
Rudski et al.,9 image modified with permission.
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Fig. 3 – Doppler echocardiographic determination of pulmonary artery (PA) diastolic pressure (PADP) and mean PA pressure
by continuous-wave Doppler signal of pulmonic regurgitation. Point 1 denotes the maximal pulmonary regurgitation (PR)
velocity at the beginning of diastole. Mean PA pressure correlates with 4 T (peak PR velocity)2 + estimated RAP. In this
example, PA mean pressure is 13 mmHg + right atrial pressure (RAP). Point 2 marks the PR velocity at end-diastole. PA
diastolic pressure is correlated with 4 T (end PR velocity)2 + estimated RAP. In this example, PADP is 6 mmHg + RAP.
Fig. 4 – Measurement of TAPSE – in this example TAPSE is 26.8 mm.
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Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.ihj.2015.12.010.
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